

Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

A.M. Oza $\mathtt{MD}(\mathtt{Lon}), ^*V.$ Castonguay $\mathtt{MD}, ^*D.$ Tsoref \mathtt{MB} Bs $\mathtt{MA}, ^*I.$ Diaz—Padilla $\mathtt{MD}, ^*K.$ Karakasis $\mathtt{MSc}, ^*H.$ Mackay $\mathtt{MD}, ^*S.$ Welch $\mathtt{MD}, ^\dagger J.$ Weberpals \mathtt{MD} $\mathtt{MSc}, ^\sharp P.$ Hoskins \mathtt{MA} \mathtt{MBB} $\mathtt{BChir}, ^\S M.$ Plante $\mathtt{MD}, ^\parallel D.$ Provencher $\mathtt{MD}, ^\# K.$ Tonkin $\mathtt{MD}, ^{**}A.$ Covens $\mathtt{MD}, ^{\dagger\dagger} P.$ Ghatage $\mathtt{MD}, ^{\sharp\sharp} J.$ Gregoire $\mathtt{MD}, ^{\S\S} H.$ Hirte $\mathtt{MD}, ^{|||} D.$ Miller $\mathtt{MD}, ^\S B.$ Rosen $\mathtt{MD}, ^{\sharp} J.$ Bentley \mathtt{MB} ChB, $^{\#\#}J.$ Maroun $\mathtt{MD}, ^{\sharp}M.$ Buyse $\mathtt{ScD}, ^{\S\S}$ C. Coens $\mathtt{MSc}, ^{****}$ M.F. Brady $\mathtt{PhD}, ^{\dagger\dagger\dagger}$ and G.C.E. Stuart $\mathtt{MD}^{\sharp\sharp\sharp\sharp}$

- * Princess Margaret Hospital, Toronto, ON.
- † London Health Sciences Centre, London, ON.
- [‡] The Ottawa Hospital, Ottawa, ON.
- § BC Cancer Agency, Vancouver, BC.
- Department of Obstetrics and Gynecology, Laval University, Laval, QC.
- Division of Gynecologic Oncology, Université de Montréal, Institut du Cancer de Montréal, Centre Recherche CHUM, Montreal, OC.
- ** Cross Cancer Institute, Edmonton, AB.
- †† Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON.
- Tom Baker Cancer Centre, Calgary, AB.
- §§ CHUQ-Hotel-Dieu de Quebec, Quebec City, QC.
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON.
- ^{##} Division of Gynecologic Oncology, Dalhousie University, Halifax, NS.
- *** European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
- ††† Roswell Park Cancer Institute, Buffalo, NY, U.S.A.
- **** University of British Columbia, Vancouver, BC.

Conflict Of Interest Disclosures

AMO has participated on advisory boards for AstraZeneca, Celgene Corporation, and Sanofi–Aventis. JW has participated on the drug advisory board for AstraZeneca. AC has served on advisory boards and speakers' bureaus for Amgen, Roche, GlaxoSmithKline, and Merck. JB has served on advisory boards for Schering–Plough and Roche. MB holds stock in IDDI.

Original Citation

Curr Oncol 2011;18(Suppl 2):S20-7. Published online September 26, 2011; corrected after print November 14, 2011.

Author's Description of Error

It has come to our attention that, over the course of putting together this article, we inadvertently forgot to include one of our colleagues, Dr. James Bentley, who had participated in initial discussions. This omission was a complete oversight on our part.

The correct author list, affiliations, and conflict of interest disclosures appear above. The error has been corrected in the HTML and PDF versions of the article.